ZA200105473B - Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia. - Google Patents

Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.

Info

Publication number
ZA200105473B
ZA200105473B ZA200105473A ZA200105473A ZA200105473B ZA 200105473 B ZA200105473 B ZA 200105473B ZA 200105473 A ZA200105473 A ZA 200105473A ZA 200105473 A ZA200105473 A ZA 200105473A ZA 200105473 B ZA200105473 B ZA 200105473B
Authority
ZA
South Africa
Prior art keywords
substituted
derivatives
utilisation
prophylaxis
therapy
Prior art date
Application number
ZA200105473A
Inventor
Gerd Steiner
Kurt Schellhaas
Wilfried Lubisch
Uta Holzenkamp
Dorothea Starck
Laszlo Szabo
Franz Emling
Garcia-Ladona Frasisco Javier
Hans-Peter Hofmann
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200105473B publication Critical patent/ZA200105473B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
ZA200105473A 1999-01-11 2001-07-03 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia. ZA200105473B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900544A DE19900544A1 (en) 1999-01-11 1999-01-11 Use of compounds of formula I for the prophylaxis and therapy of cerebral ischemia

Publications (1)

Publication Number Publication Date
ZA200105473B true ZA200105473B (en) 2002-10-03

Family

ID=7893835

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200105473A ZA200105473B (en) 1999-01-11 2001-07-03 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.

Country Status (19)

Country Link
EP (1) EP1140099A1 (en)
JP (1) JP2002534467A (en)
KR (1) KR20010101440A (en)
CN (1) CN1333685A (en)
AR (1) AR029741A1 (en)
AU (1) AU2285100A (en)
BG (1) BG105688A (en)
BR (1) BR9916888A (en)
CA (1) CA2359390A1 (en)
DE (1) DE19900544A1 (en)
HU (1) HUP0200520A3 (en)
IL (1) IL144145A0 (en)
MX (1) MXPA01006966A (en)
NO (1) NO20013408L (en)
PL (1) PL348916A1 (en)
SK (1) SK9682001A3 (en)
TR (1) TR200102009T2 (en)
WO (1) WO2000041697A1 (en)
ZA (1) ZA200105473B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
EP1667979A4 (en) * 2003-09-23 2007-04-18 Merck & Co Inc Isoquinoline potassium channel inhibitors
BRPI0615248A2 (en) * 2005-08-26 2009-07-14 Shionogi & Co derivative having ppar agonist activity
KR20100063087A (en) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
MA41168A (en) 2014-12-17 2017-10-24 Acraf NEW ANTIBACTERIAL COMPOUNDS
CN108484594B (en) * 2018-02-09 2020-08-04 福建医科大学 Alkoxy substituted tetrahydropyridopyrimidine compound or available salt thereof, and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3620643A1 (en) * 1985-06-22 1987-01-22 Sandoz Ag Thiazoles, their preparation and use
DE3831888A1 (en) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg MEDICINES FOR TREATING APOPLEXIA CEREBRI
JP3036789B2 (en) * 1990-06-22 2000-04-24 三井化学株式会社 Novel heterocyclic compounds and pharmaceutical compositions
DE19746612A1 (en) * 1997-10-22 1999-04-29 Basf Ag New 2-substituted 1,2-benzisothiazole derivatives
DE19747063A1 (en) * 1997-10-24 1999-04-29 Basf Ag New 3-substituted tetrahydropyridopyrimidinone derivatives

Also Published As

Publication number Publication date
HUP0200520A2 (en) 2002-07-29
BR9916888A (en) 2001-11-20
DE19900544A1 (en) 2000-07-13
AR029741A1 (en) 2003-07-16
CA2359390A1 (en) 2000-07-20
JP2002534467A (en) 2002-10-15
KR20010101440A (en) 2001-11-14
BG105688A (en) 2002-02-28
WO2000041697A1 (en) 2000-07-20
MXPA01006966A (en) 2002-04-10
AU2285100A (en) 2000-08-01
CN1333685A (en) 2002-01-30
HUP0200520A3 (en) 2003-04-28
TR200102009T2 (en) 2002-01-21
NO20013408L (en) 2001-08-21
IL144145A0 (en) 2002-05-23
NO20013408D0 (en) 2001-07-10
PL348916A1 (en) 2002-06-17
SK9682001A3 (en) 2002-03-05
EP1140099A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
HK1051695A1 (en) N6 heterocyclic 8-modified andenosine derivatives.
HUP0104917A3 (en) Azepinoindole derivatives, the production and use thereof
ZA200201494B (en) Benzodiazepin derivatives, the production and use thereof.
ZA200107989B (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof.
MXPA02008801A (en) Indole derivatives, process for preparation of the same and use thereof.
ZA200006577B (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors.
HRP20020375A2 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
ZA200107689B (en) 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
HK1047588A1 (en) 2-Amino-4H-3,1-benzoxazine-4-one derivatives for the treatment of obesity
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
HK1043321A1 (en) Use of macrolide compounds for the treatment of dry eye.
HK1049655A1 (en) Substituted norbornylamino derivatives, productionand use thereof and medicaments containing them.
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
PL343728A1 (en) Carbapenem derivatives, utilization thereof and intermediate compounds of the same
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200105473B (en) Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia.
MXPA01013465A (en) Use of cortisol antagonists in the treatment for heat failure.
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
ZA995212B (en) The use of aryl-cyclohexylamine derivatives against CNS disorders.
AU2001252254A1 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparationthereof and use thereof
HU9900123D0 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
ZA200110351B (en) Bycyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof.
GB2350361B (en) 3,4,5-tricyanophenyl derivatives